ÂÜÀòÂÒÂ×

Oliver Sims is a seasoned venture capitalist specializing in biotech and life sciences, currently associated with Octopus Ventures, which manages a £2 billion AUM fund, since January 2023. Sims engages in various roles including Board Observer and Investor at Biofidelity and Ori Biotech, focusing on genomic diagnostics and cell and gene therapy manufacturing hardware, respectively. Additionally, Sims serves as a Non-Executive Director for multiple companies, including LabGenius, ExpressionEdits, Infinitopes, CellVoyant, NanoSyrinx, Pear Bio, and Pencil Biosciences Limited, contributing expertise in areas such as AI-driven therapeutic development, gene modulation, and cancer vaccine research. Educational credentials include an Accelerator degree in Entrepreneurship from Cambridge Judge Business School, a MicroMasters in Accounting and Business Foundations from The University of British Columbia, and a Bachelor's degree in Biomedical Science from Royal Holloway, University of London.